Perceptive Advisors LLC bought a new position in shares of Keryx Biopharmaceuticals (NASDAQ:KERX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 83,386 shares of the biopharmaceutical company’s stock, valued at approximately $592,000. Perceptive Advisors LLC owned approximately 0.07% of Keryx Biopharmaceuticals as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Fox Run Management L.L.C. purchased a new stake in shares of Keryx Biopharmaceuticals during the third quarter worth $101,000. Engineers Gate Manager LP purchased a new stake in shares of Keryx Biopharmaceuticals during the third quarter worth $102,000. Principal Financial Group Inc. grew its holdings in shares of Keryx Biopharmaceuticals by 4.2% during the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 590 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Keryx Biopharmaceuticals by 51.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 5,628 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Keryx Biopharmaceuticals during the second quarter worth $183,000. 64.82% of the stock is owned by institutional investors and hedge funds.
Shares of Keryx Biopharmaceuticals (NASDAQ KERX) traded up $0.26 on Tuesday, hitting $4.91. 1,211,534 shares of the company were exchanged, compared to its average volume of 1,141,650. The company has a debt-to-equity ratio of 13.95, a current ratio of 4.46 and a quick ratio of 3.76. Keryx Biopharmaceuticals has a 12-month low of $4.33 and a 12-month high of $8.38. The stock has a market capitalization of $583.06, a price-to-earnings ratio of -3.27 and a beta of 4.94.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.03). The firm had revenue of $15.00 million during the quarter, compared to analysts’ expectations of $18.88 million. Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The company’s revenue for the quarter was up 138.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.39) EPS. equities analysts anticipate that Keryx Biopharmaceuticals will post -1.36 EPS for the current year.
A number of equities research analysts have recently issued reports on KERX shares. Zacks Investment Research lowered shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 8th. Stifel Nicolaus dropped their price objective on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a report on Wednesday, November 8th. Finally, ValuEngine lowered shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company. Keryx Biopharmaceuticals currently has an average rating of “Hold” and a consensus price target of $7.35.
ILLEGAL ACTIVITY NOTICE: “83,386 Shares in Keryx Biopharmaceuticals (KERX) Acquired by Perceptive Advisors LLC” was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.truebluetribune.com/2018/01/03/perceptive-advisors-llc-buys-new-position-in-keryx-biopharmaceuticals-kerx.html.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.